Research Twice-yearly injectable PrEP is highly effective for gay men and trans individuals By Liz Highleyman
Research New numbers reveal the state of the HIV epidemic in the U.S. By San Francisco AIDS Foundation
Research Groundbreaking new report highlights overdose prevention needs of Latino/x communities in San Francisco By San Francisco AIDS Foundation
Research “Heartbreak and power”: What we learned about the needs of transgender community members over age 50 By Charles Orgbon III
Research Medical Experts Encourage People Living with HIV Receive the COVID-19 Vaccine By Meagan Williams and San Francisco AIDS Foundation
Research Injectable PrEP Offers a New Option for Women By Liz Highleyman and San Francisco AIDS Foundation
Research HIV trends: ‘One-size-fits-all’ fails our communities By Emily Land, MA and San Francisco AIDS Foundation
Research Does PrEP work for trans people taking gender-affirming hormones? Yes, says new research By Emily Land, MA
Research “Tremendously exciting” news of cabotegravir long-acting injectable for PrEP shared at AIDS 2020 By Emily Land, MA
Research AIDS 2020: Our innovations in HIV, PrEP, sexual health & harm reduction By San Francisco AIDS Foundation
Research PrEP injectable found to be “highly effective” for HIV prevention in HPTN study By Emily Land, MA
Research For people with HIV, cannabis use linked to lower rates of cognitive impairment By Emily Land, MA
